BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29680008)

  • 1. Secondary mucinous carcinoma of the prostate after low dose rate brachytherapy.
    Murchison SC; Martens MB; Truong P; Alexander A
    Can J Urol; 2018 Apr; 25(2):9284-9287. PubMed ID: 29680008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.
    Tseng TY; Sevilla DW; Moul JW; Maloney KE
    Prostate Cancer Prostatic Dis; 2006; 9(2):195-7. PubMed ID: 16568146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.
    Syed AM; Puthawala A; Sharma A; Gamie S; Londrc A; Cherlow JM; Damore SJ; Nazmy N; Sheikh KM; Ko SJ
    Cancer Control; 2001; 8(6):511-21. PubMed ID: 11807421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy.
    Komiya A; Fujiuchi Y; Ito T; Morii A; Yasuda K; Watanabe A; Nozaki T; Iida H; Nomura K; Fuse H
    Int J Urol; 2013 Feb; 20(2):185-92. PubMed ID: 22905941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Schaar S; Borchers H; Heidenreich A; Eble MJ
    Radiother Oncol; 2010 Jul; 96(1):25-9. PubMed ID: 20231039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
    D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
    Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience].
    Mallet F; Wdowczyk D; Bruna A; Villena P; Herard A; Amory JP; Joffroy P; Pangrazzi T
    Cancer Radiother; 2010 Jan; 14(1):11-8. PubMed ID: 20005765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of brachytherapy in the definitive management of prostate cancer.
    Crook J
    Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
    Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
    Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
    Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
    BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
    Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose rate prostate brachytherapy].
    Nickers P; Blanchard P; Hannoun-Lévi JM; Bossi A; Chapet O; Guérif S
    Cancer Radiother; 2013 Apr; 17(2):118-24. PubMed ID: 23578898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectourethral fistula after combination radiotherapy for prostate cancer.
    Marguet C; Raj GV; Brashears JH; Anscher MS; Ludwig K; Mouraviev V; Robertson CN; Polascik TJ
    Urology; 2007 May; 69(5):898-901. PubMed ID: 17482930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.